The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Direct thrombin inhibitors
Open accessAbstract
Heparins and vitamin K antagonists have been the primary agents used for anticoagulation in certain cardiovascular and thromboembolic diseases for over 50 years. However, they can be difficult to administer and are fraught with limitations. In response to the need for new anticoagulants, direct thrombin inhibitors (DTIs) have been developed and investigated for their utility in prophylaxis and treatment of venous thromboembolism (VTE), heparin‐induced thrombocytopenia (HIT), acute coronary syndromes (ACS), secondary prevention of coronary events after ACS, and nonvalvular atrial fibrillation. Currently, four parenteral direct inhibitors of thrombin activity are FDA‐approved in North America: lepirudin, desirudin, bivalirudin and argatroban. Of the new oral DTIs, dabigatran etexilate is the most studied and promising of these agents. This review discusses the clinical indications and efficacy of these direct thrombin inhibitors as well as future directions in anticoagulant therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,162
Weitz, J. I., Hudoba, M., Massel, D., Maraganore, J., & Hirsh, J. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114723 · Cited by 1,123
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
ERIKSSON, B. I., DAHL, O. E., ROSENCHER, N., KURTH, A. A., VAN DIJK, C. N., FROSTICK, S. P., KÄLEBO, P., CHRISTIANSEN, A. V., HANTEL, S., HETTIARACHCHI, R., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02748.x · Cited by 979
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
The Structure of a Complex of Recombinant Hirudin and Human α-Thrombin
Rydel, T. J., Ravichandran, K. G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C., & Fenton, J. W. (1990) · Science · doi:10.1126/science.2374926 · Cited by 709
Simoons, M. L. (1996) · RePub (Erasmus University Rotterdam) · Cited by 706
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Newly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes
(1996) · New England Journal of Medicine · doi:10.1056/nejm199609123351103 · Cited by 660
Di Nisio, M., Middeldorp, S., & Büller, H. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044440 · Cited by 655
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
(2009) · The Journal of Arthroplasty · doi:10.1016/j.arth.2008.01.132 · Cited by 631
Eriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., Pedersen, K. E., Lionetti, D. A., Stangier, J., & Wallentin, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.034 · Cited by 419
Xiao, Z., & Théroux, P. (1998) · Circulation · doi:10.1161/01.cir.97.3.251 · Cited by 382
Eriksson, B. I., Wille-Jørgensen, P., Kälebo, P., Mouret, P., Rosencher, N., Bösch, P., Baur, M., Ekman, S., Bach, D., Lindbratt, S., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711063371901 · Cited by 370
Stangier, J., & Clemens, A. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609343004 · Cited by 337
Bittl, J. A., Chaitman, B. R., Feit, F., Kimball, W., & Topol, E. J. (2001) · American Heart Journal · doi:10.1067/mhj.2001.119374 · Cited by 313
Stangier, J., Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Nehmiz, G., Stähle, H., Rathgen, K., & Svärd, R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274550 · Cited by 296
Weitz, J. I., Leslie, B., & Hudoba, M. (1998) · Circulation · doi:10.1161/01.cir.97.6.544 · Cited by 194
Stangier, J., Stähle, H., Rathgen, K., Roth, W., & Shakeri‐Nejad, K. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008324179 · Cited by 177
Mahaffey, K. W., Lewis, B., Wildermann, N. M., Berkowitz, S. D., Oliverio, R. M., Turco, M. A., Shalev, Y., Lee, P. V., Traverse, J. H., Rodriguez, A., et al. (2003) · PubMed · Cited by 166
Drug-Induced Liver Injury in Humans: The Case of Ximelagatran
Keisu, M., & Andersson, T. B. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_13 · Cited by 163
Hirsh, J., O'Donnell, M. J., & Weitz, J. I. (2004) · Blood · doi:10.1182/blood-2003-12-4195 · Cited by 157
Weitz, J. I., Hirsh, J., & Samama, M. M. (2004) · CHEST Journal · doi:10.1378/chest.126.3_suppl.265s · Cited by 154
Drug and dietary interactions of the new and emerging oral anticoagulants
Walenga, J. M., & Adıgüzel, C. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02286.x · Cited by 152
Eriksson, B. I., Ekman, S., Lindbratt, S., Baur, M., Bach, D., Tørholm, C., Kälebo, P., & Close, P. (1997) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-199703000-00002 · Cited by 138
Coadministration of Dabigatran Etexilate and Atorvastatin
Stangier, J., Rathgen, K., Stähle, H., Reseski, K., Körnicke, T., & Roth, W. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256595 · Cited by 96
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves
McKellar, S. H., Abel, S. A., Camp, C. L., Suri, R. M., Ereth, M. H., & Schaff, H. V. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.02.011 · Cited by 85
Hirudins: Antithrombin Anticoagulants
Stringer, K. A., & Lindenfeld, J. M. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202601211 · Cited by 75
Mäegdefessel, L., Linde, T., Krapiec, F., Hamilton, K. F., Steinseifer, U., van Ryn, J., Raaz, U., Buerke, M., Werdan, K., & Schlitt, A. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.06.011 · Cited by 52
Rasmussen, L. E., Tveit, A., Jensen, E. C., Wessman, P., Panfilov, S., Wåhlander, K., & Olsson, B. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-07-0509 · Cited by 52
New oral anticoagulants: a practical guide for clinicians
Wittkowsky, A. K. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0409-0 · Cited by 51
New Anticoagulant Agents: Direct Thrombin Inhibitors
Nutescu, E. A., Shapiro, N. L., & Chevalier, A. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.12.005 · Cited by 48
Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors
Steffel, J., & Lüscher, T. F. (2009) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32832edac0 · Cited by 27
The current role of anticoagulants in cardiovascular medicine
Caterina, R. D. (2009) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32832e490b · Cited by 24
Cited by
A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Flora, G. D., & Nayak, M. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190925163827 · Cited by 476
Bordon, K. D. C. F., Cologna, C. T., Fornari-Baldo, E. C., Pinheiro-Júnior, E. L., Cerni, F. A., Amorim, F. G., Anjolette, F. A. P., Cordeiro, F. A., Wiezel, G. A., Cardoso, I. A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01132 · Cited by 303
Radke, D., Jia, W., Sharma, D., Fena, K., Wang, G., Goldman, J., & Zhao, F. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701461 · Cited by 256
Metelli, A., Wu, B. X., Riesenberg, B., Guglietta, S., Huck, J. D., Mills, C., Li, A., Rachidi, S., Krieg, C., Rubinstein, M. P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay4860 · Cited by 139
“In this study, we used dabigatran etexilate, a competitive and reversible direct thrombin inhibitor approved for venous thrombolytic events (46).”
MethodNative metabolomics identifies the rivulariapeptolide family of protease inhibitors
Reher, R., Aron, A. T., Fajtová, P., Stincone, P., Wagner, B., Pérez-Lorente, A. I., Liu, C., Shalom, I. Y. B., Bittremieux, W., Wang, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32016-6 · Cited by 53
Metadata
- Authors
- Lee, C. J., & Ansell, J. E.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2011-09-09
- Volume
- 72
- Issue
- 4
- Pages
- 581-592
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1482291463
- Cited by
- 272
- References
- 42
- FWCI
- 13.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.